BioCentury
ARTICLE | Finance

Taking Tesaro

How the team behind Tesaro delivered its $5.1 billion takeout

December 7, 2018 10:36 PM UTC

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced plans on Monday to acquire Tesaro for $75 per share, a 62% premium to Tesaro’s close of $46.38 on Friday, before the deal was announced...

BCIQ Company Profiles

GSK plc

Tesaro Inc.